MedPath

Multimodal Sexual Dysfunction Intervention In HCT

Not Applicable
Active, not recruiting
Conditions
Sexual Dysfunction
Hematopoietic Stem Cell Transplantation
Hematologic Diseases
Interventions
Behavioral: Enhanced Standard Care
Behavioral: Multimodal Intervention to Address Sexual Dysfunction
Registration Number
NCT03803696
Lead Sponsor
Massachusetts General Hospital
Brief Summary

This research study is evaluating the impact of an intervention to improve sexual function in stem cell transplant survivors on participants' sexual function, quality of life, and mood.

It is expected that about 120 people who have undergone a stem cell transplant will take part in this research study.

Detailed Description

Frequently survivors of stem cell transplantation report significant problems with their sexual function that impacts their quality of life, mood, and their intimacy and relationship with their partners. These issues can be very distressing to patients and their loved ones. The Investigators want to know if the introduction of an intervention focused on improving sexual function may improve a participant's overall care and quality of life.

The main purpose of this study is to compare two types of care - the study intervention versus enhanced standard care which includes receiving an educational handout about sexual dysfunction. The main goal is to assess if the intervention will improve participant's sexual function, quality of life, and mood.

The intervention includes a comprehensive assessment by a transplant clinician (a transplant physician or nurse practitioner) who is trained in sexual dysfunction assessment to explore the reasons for sexual dysfunction and focus on ways to improve symptoms.

-- If the transplant clinician feels additional help is needed by a sexual health expert, the participant will be referred to the sexual health clinic. In the sexual health clinic, the participant will be evaluated by an expert physician who will also focus on strategies to improve sexual function.

The study will use a series of questionnaires to measure sexual function, quality of life, physical symptoms, and mood. Study questionnaires will be completed in the clinic or remotely with assistance provided as needed.

.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
230
Inclusion Criteria
  • Adult patients (≥ 18 years) with hematologic malignancy who underwent autologous or allogeneic HCT ≥ three months prior to study enrollment.
  • Positive screen for sexual dysfunction that is causing distress based on the National Comprehensive Cancer Network (NCCN) survivorship guidelines
  • Ability to read and respond to questions in English or to complete questionnaires with assistance from an interpreter.
Exclusion Criteria
  • Patients with relapsed disease requiring treatment
  • Patients with a planned second transplant
  • Patients > 5 years from their HCT
  • Patients with psychiatric or cognitive conditions which the treating clinicians believes prohibits compliance with study procedures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Enhanced Standard CareEnhanced Standard Care* Baseline data collection, registration and randomization * Inform primary transplant clinician of sexual dysfunction causing distress * Receive American Cancer Society sexual educational material
Multimodal Intervention to Address Sexual DysfunctionMultimodal Intervention to Address Sexual Dysfunction* Baseline data collection, registration and randomization * 3 Monthly visits with trained study nurse practitioners * Referral to specialist if * Psychological etiology * Sexual Trauma * Relationship Discord * Concern for Malignancy or anatomic scarring requiring surgery
Primary Outcome Measures
NameTimeMethod
Compare Patient Global Satisfaction with Sex3 Months

compare patients' global satisfaction with sex using PROMIS Sexual Function and Satisfaction Measure (global satisfaction domain) at three months between the study groups using linear regression controlling for baseline values (as necessary for any imbalances in baseline variables

Secondary Outcome Measures
NameTimeMethod
For females: compare patient-reported vaginal comfort longitudinallyup to 6 months

compare (PROMIS Sexual Function and Satisfaction Measure - vaginal comfort domain) longitudinally between the two study groups

Compare Patient Reported Quality of Life3 Months

Compare patient-reported QOL using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT)

Compare Patient Reported Anxiety Symptoms Longitudinallyup to 6 months

Compare patient reported anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS- anxiety subscale) longitudinally between the two study groups. Subscale ranges from 0-21 with higher score indicating higher anxiety symptoms

Compare Patient Reported Depression Symptoms3 Months

Compare Patient Reported Depression Symptoms using the Hospital Anxiety and Depression Scale (HADS - depression subscale). Subscale ranges from 0-21 with higher score indicating higher depression symptoms

Compare Patient Reported Depression Symptoms Longitudinallyup to 6 Months

Compare Patient Reported Depression Symptoms using the Hospital Anxiety and Depression Scale (HADS - depression subscale) longitudinally between the two study groups. Subscale ranges from 0-21 with higher score indicating higher depression symptoms

For females: compare patient-reported vaginal lubrication longitudinallyup to 6 months

compare (PROMIS Sexual Function and Satisfaction Measure - lubrication domain) longitudinally between the two study groups

For females: compare patient-reported vaginal comfort3 months

compare (PROMIS Sexual Function and Satisfaction Measure - vaginal comfort domain

Compare patient-reported orgasm3 Months

Compare PROMIS Sexual Function and Satisfaction Measure - Orgasm domain

Compare patient-reported orgasm longitudinallyup to 6 months

Compare PROMIS Sexual Function and Satisfaction Measure - Orgasm domain) longitudinally between the study groups

Compare Patient global satisfaction with sex longitudinallyup to 6 months

compare PROMIS Sexual function and Satisfaction Measure - global satisfaction with sex domain) longitudinally between study groups

Compare Patient reported interest in sexual activity longitudinallyup to 6 months

compare PROMIS Sexual Function and Satisfaction Measure Interest in sexual activity domain) longitudinally between study groups

For males: compare patient-reported erectile function longitudinallyup to 6 months

Compare PROMIS Sexual Function and Satisfaction Measure - Erectile function domain longitudinally between the two groups

Compare Patient reported interest in sexual activity3 Months

PROMIS Sexual Function and Satisfaction Measure Interest in sexual activity domain)

Compare Patient Reported Anxiety Symptoms3 Months

Compare patient reported anxiety symptoms using the Hospital Anxiety and Depression Scale (HADS- anxiety subscale). Subscale ranges from 0-21 with higher score indicating higher anxiety symptoms

For males: compare patient-reported erectile function3 Months

PROMIS Sexual Function and Satisfaction Measure - Erectile function domain

For females: compare patient-reported vaginal lubrication3 Months

compare (PROMIS Sexual Function and Satisfaction Measure - lubrication domain)

Compare Patient Reported Quality of Life longitudinallyup to 6 months

Compare patient-reported QOL using the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT) longitudinally between the two groups

Trial Locations

Locations (1)

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath